AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3053314 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of ethanol consumption
Number of subjects: 221
Study 1101838 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (300 to 450 mg daily)
Number of subjects: 41
Study 1101838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (10 weeks, 3 sessions per week, 60 minutes each session)
Number of subjects: 62
Study 31221931 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 62
Study 31221931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 62
Study 28259496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 3
Study 28259496 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Number of subjects: 3
Study 28259496 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Acupuncture and SMT
Number of subjects: 3
Study 28259496 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study 26459336 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal unconditional cash transfers
Number of subjects: 0
Study 26459336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh food vouchers
Number of subjects: 0
Study 26459336 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided by the ACF programme
Number of subjects: 0
Study 22544562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month program of tailored materials designed to increase fruit and vegetable (F&V) intake, decrease fat intake, and/or increase physical activity (PA)
Number of subjects: 543
Study 22544562 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in self-efficacy for physical activity (PA)
Number of subjects: 543
Study 21300181 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication‐Competent Adenovirus‐mediated Suicide Gene Therapy followed by radiation (Arm 1)
Number of subjects: 280
Study 21300181 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (Arm 2)
Number of subjects: 280
Study 19671200 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 10
Study 19671200 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study 17201456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone with rifampicin
Number of subjects: 0
Study 17201456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone with rifampicin
Number of subjects: 0
Study 17201456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone with gemfibrozil
Number of subjects: 0
Study 17201456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone with gemfibrozil
Number of subjects: 0
Study 17201456 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone and pioglitazone
Number of subjects: 0
Study 15587768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 752
Study 15587768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 752
Study 15587768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study 11181193 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 84
Study 11181193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm
Number of subjects: 84
Study 11181193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm plus desmopressin
Number of subjects: 84
Study 11181193 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (for nonresponders)
Number of subjects: 84
Study 9273185 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy (cisplatin 50 mg/m2 on days 1 and 2, fluorouracil 1 gr/m2 continuous infusion on days 1, 2, and 3, external beam irradiation 20 Gy in 2 Gy fractions from days 1 to 12)
Number of subjects: 39
Study 9273185 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy
Number of subjects: 39
Study 7962895 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior resin-bonded bridges (PRBBs) placed in maxilla
Number of subjects: 45
Study 7962895 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior resin-bonded bridges (PRBBs) placed in mandible
Number of subjects: 45
Study 2440632 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg three times a day)
Number of subjects: 10
Study 2440632 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (200 mg three times a day)
Number of subjects: 10
Study 29127949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus intravitreous dexamethasone implant (700 μg)
Number of subjects: 116
Study 29127949 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.3 mg) alone
Number of subjects: 116
Study 26091907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate+golimumab)
Number of subjects: 234
Study 26091907 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-monotherapy
Number of subjects: 234
Study 26091907 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week MRI
Number of subjects: 234
Study 26091907 — intervention group
Group type: COMPARATOR
Intervention: 1-year X-ray
Number of subjects: 234
Study 26091907 — intervention group
Group type: COMPARATOR
Intervention: 52-week vdHS
Number of subjects: 234
Study 25172879 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (daily motivational messages about nutrition and physical activity)
Number of subjects: 100
Study 25172879 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper-based information about healthy lifestyle)
Number of subjects: 100
Study 23649400 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bone intramedullary fixation
Number of subjects: 24
Study 23649400 — intervention group
Group type: COMPARATOR
Intervention: Both-bone intramedullary fixation
Number of subjects: 24
Study 20723012 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia fixed dental prostheses with preliminary mechanical damage (defined saw cuts)
Number of subjects: 40
Study 20723012 — intervention group
Group type: COMPARATOR
Intervention: Zirconia fixed dental prostheses without preliminary damage (control group)
Number of subjects: 40
Study 20723012 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia fixed dental prostheses (both damaged and undamaged) subjected to artificial aging by TMC
Number of subjects: 40
Study 19020127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-midazolam
Number of subjects: 40
Study 19020127 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 15779328 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention to target stimuli
Number of subjects: 11
Study 15779328 — intervention group
Group type: COMPARATOR
Intervention: Passive observation of visual symbols
Number of subjects: 11
Study 14699230 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomadura vinacea (provisionally identified)
Number of subjects: 2
Study 14699230 — intervention group
Group type: COMPARATOR
Intervention: Actinomadura pelletieri (known red grain mycetoma agent)
Number of subjects: 2
Study 12612294 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 16 weeks
Number of subjects: 639
Study 12612294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 10447578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolatrexed 725 mg/m(2)/day by continuous infusion for 5 days
Number of subjects: 54
Study 10447578 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m(2) as rapid intravenous infusion every 3 weeks
Number of subjects: 54
Study 7783102 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (7.1 pM/kg per min) during euglycemic hyperinsulinaemic glucose clamp
Number of subjects: 37
Study 7783102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting intracellular (erythrocyte) magnesium concentrations
Number of subjects: 37
Study 7783102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin concentrations
Number of subjects: 37
Study 2245049 — intervention group
Group type: EXPERIMENTAL
Intervention: Plegisol
Number of subjects: 50
Study 2245049 — intervention group
Group type: COMPARATOR
Intervention: O2-Plegisol
Number of subjects: 50
Study 2245049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg IV
Number of subjects: 116
Study 569995 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 116
Study 31965358 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical Volume Element (SVE) model
Number of subjects: 0
Study 31965358 — intervention group
Group type: COMPARATOR
Intervention: Representative Volume Element (RVE) model
Number of subjects: 0
Study 31786228 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term stenting (1 week)
Number of subjects: 37
Study 31786228 — intervention group
Group type: COMPARATOR
Intervention: Standard stenting (4 weeks)
Number of subjects: 37
Study 27324337 — intervention group
Group type: EXPERIMENTAL
Intervention: non-opioid/opioid analgesic combinations plus topical 0.25% bupivacaine onto the cystic plate and local 0.25% bupivacaine port-site injection
Number of subjects: 63
Study 27324337 — intervention group
Group type: COMPARATOR
Intervention: non-opioid/opioid analgesic combinations (Control Group)
Number of subjects: 63
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 12.5 mg SC
Number of subjects: 70
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 125 mg SC
Number of subjects: 70
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 250 mg SC
Number of subjects: 70
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg IV
Number of subjects: 70
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC doses providing 50% inhibition
Number of subjects: 70
Study 26445140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC doses providing 90% inhibition
Number of subjects: 70
Study 23407222 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 21
Study 23407222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20670958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose MMF therapy
Number of subjects: 901
Study 20670958 — intervention group
Group type: COMPARATOR
Intervention: Concentration-controlled MMF therapy
Number of subjects: 901
Study 19810000 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS) system
Number of subjects: 599
Study 19810000 — intervention group
Group type: COMPARATOR
Intervention: No computerized clinical decision support (CDS) system
Number of subjects: 599
Study 19810000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherers to EBPG
Number of subjects: 599
Study 19810000 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherers to EBPG
Number of subjects: 599
Study 16625234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 4159
Study 16625234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 15659929 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard transurethral resection of prostate (TURP)
Number of subjects: 50
Study 15659929 — intervention group
Group type: COMPARATOR
Intervention: Transurethral vaporesection (TUVRP) with various loops
Number of subjects: 50
Study 15659929 — intervention group
Group type: COMPARATOR
Intervention: Standard TURP and TUVRP
Number of subjects: 50
Study 11742962 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily T‐piece weaning or pressure support
Number of subjects: 16
Study 11742962 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation with back‐up noninvasive positive‐pressure ventilation
Number of subjects: 16
Study 11742962 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 16
Study 9264481 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 IU bolus + 1000 to 1200 U/h infusion, n=371)
Number of subjects: 909
Study 9264481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hirudin (0.2 mg/kg bolus + 0.10 mg x kg(‐1) x h(‐1) infusion, n=271)
Number of subjects: 909
Study 9264481 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose hirudin (0.4 mg/kg bolus + 0.15 mg x kg(‐1) x h(‐1) infusion, n=267)
Number of subjects: 909
Study 8219662 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (pH 8.0)
Number of subjects: 30
Study 8219662 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation C (pH 10.2)
Number of subjects: 30
Study 8219662 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of preparations A and E
Number of subjects: 30
Study 8219662 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 30
Study 29673465 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 23953
Study 29673465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 23953
Study 29673465 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 23953
Study 29673465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen with aspirin
Number of subjects: 23953
Study 29673465 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen with aspirin
Number of subjects: 23953
Study 27888995 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV plus oxygen therapy
Number of subjects: 18
Study 27888995 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 18
Study 24722649 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 21
Study 23006736 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (xanthine oxidase inhibitor)
Number of subjects: 0
Study 23006736 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (uricosuric)
Number of subjects: 0
Study 23006736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20799399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunovac‐VP4 vaccine
Number of subjects: 69
Study 20799399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Immunovac‐VP4 vaccine
Number of subjects: 69
Study 18388929 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF (2.5 ml at 0.2 mg/ml, 8 intramuscular injections on days 1, 15, 30, and 45)
Number of subjects: 125
Study 18388929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 18388929 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF
Number of subjects: 125
Study 15727045 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality play
Number of subjects: 16
Study 15727045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine VR environments
Number of subjects: 16
Study 12775947 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 10727077 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin antioxidant mixture (600 mg alpha‐tocopherol, 1,000 mg vitamin C, 32 mg beta‐carotene)
Number of subjects: 0
Study 10727077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8889119 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 0
Study 8889119 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1 hour of treadmill walking at 50% maximum oxygen uptake)
Number of subjects: 0
Study 8889119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0
Study 8889119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8889119 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol
Number of subjects: 0
Study 1510435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ceftazidime (1-g dose)
Number of subjects: 12
Study 1510435 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal administration of ceftazidime (1-g dose)
Number of subjects: 12
Study 1510435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of ceftazidime (1-g dose)
Number of subjects: 12
Study 6091247 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17
Number of subjects: 0
Study 6091247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30935665 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with persistent indoor-air-related symptoms
Number of subjects: 52
Study 30935665 — intervention group
Group type: COMPARATOR
Intervention: General population (comparison group)
Number of subjects: 52
Study 30935665 — intervention group
Group type: COMPARATOR
Intervention: Individuals with asthma (comparison group)
Number of subjects: 52
Study 30935665 — intervention group
Group type: COMPARATOR
Intervention: Individuals with anxiety and depressive disorder (comparison group)
Number of subjects: 52
Study 30935665 — intervention group
Group type: COMPARATOR
Intervention: Individuals with chronic conditions with work disability (comparison group)
Number of subjects: 52
Study 29722796 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 396
Study 29722796 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 396
Study 26079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine orthoses (Vertebradyn‐Strong)
Number of subjects: 30
Study 26079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine orthoses (Horizon 637 LSO)
Number of subjects: 30
Study 26079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine orthoses (SofTec Dorso)
Number of subjects: 30
Study 26079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip orthoses (DynaCox and Hohmann‐like orthosis)
Number of subjects: 30
Study 26079866 — intervention group
Group type: COMPARATOR
Intervention: All orthoses
Number of subjects: 30
Study 25376414 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health intervention designed to reduce prolonged occupational sitting
Number of subjects: 0
Study 25376414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 22139751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs‐cTnT) measured at randomization and after 3 months (GISSI‐HF) or 4 months (Val‐HeFT) follow-up.
Number of subjects: 5284
Study 22139751 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in hs‐cTnT concentration over time.
Number of subjects: 5284
Study 20197487 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg, 700 mg, 1400 mg, or 2100 mg of artemisinin-naphthoquine phosphate
Number of subjects: 28
Study 20197487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of artemisinin and naphthoquine phosphate
Number of subjects: 28
Study 20197487 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 28
Study 20197487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose administration
Number of subjects: 28
Study 17905357 — intervention group
Group type: EXPERIMENTAL
Intervention: GengNianAn (GNA) formula, taken twice daily for 12 weeks
Number of subjects: 69
Study 17905357 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken twice daily for 12 weeks
Number of subjects: 69
Study 14999424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 41
Study 14999424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11905547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 microg metered dose inhaler (MDI) administered by Fluspacer
Number of subjects: 50
Study 11905547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9527090 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 100
Study 9527090 — intervention group
Group type: COMPARATOR
Intervention: Brachial approach
Number of subjects: 100
Study 7843761 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 115
Study 7843761 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 115
Study 7843761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 2146282 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (1600 mg/day, orally)
Number of subjects: 8
Study 2146282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31757 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine anaesthesia (4 mg/kg before skin incision)
Number of subjects: 12
Study 31757 — intervention group
Group type: COMPARATOR
Intervention: Fluroxene anaesthesia
Number of subjects: 12
Study 31499206 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rifampicin (SDR) after BCG vaccination
Number of subjects: 14988
Study 31499206 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination only (Control)
Number of subjects: 14988
Study 28190236 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational intervention for carers including initial telephone assessment, personalized resource file, nurse-led home visit, ongoing telephone support
Number of subjects: 10
Study 28190236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 10
Study 28190236 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-IS intervention
Number of subjects: 10
Study 27502846 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 12944
Study 27502846 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 12944
Study 27502846 — intervention group
Group type: EXPERIMENTAL
Intervention: No/trace albuminuria
Number of subjects: 12944
Study 24880843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligners with attachment
Number of subjects: 30
Study 24880843 — intervention group
Group type: COMPARATOR
Intervention: Aligners without attachment
Number of subjects: 30
Study 24880843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligners for maxillary incisor torque
Number of subjects: 30